Table S1 Search strategy used in this review

| Databases	Terms
LILACS	((carcinoma de pulmón de células no pequeñas) OR (cáncer pulmonar de células no pequeñas) OR (adenocarcinoma) OR (carcinoma de células escamosas) OR (neoplasias pulmonares) OR (cáncer pulmonar)) AND ((hispanoamericanos) OR (hispanos) OR (latinas) OR (latinos)) AND (pd-l1) OR (pd-1) OR (pd-1/pd-l1) OR (proteína de muerte programada 1) OR (proteína pd-1) OR (receptor 1 de muerte celular programada) OR (receptor de muerte celular programada 1) OR (ligando de muerte celular programada 1)
Embase and Medline	#1. 'carcinoma, non-small-cell lung'/exp OR 'carcinoma, non-small-cell lung' OR (('carcinoma,'/exp OR carcinoma,) AND 'non small cell' AND ('lung'/exp OR lung)) #2. ('carcinoma,'/exp OR carcinoma,) AND non AND small AND ('cell'/exp OR cell) AND ('lung'/exp OR lung) #3. 'non small cell lung cancer' #4. 'non small' AND cell AND lung AND cancer #5. nonsmall AND cell AND lung AND cancer #6. 'squamous cell carcinoma' #7. 'adenocarcinoma' #8. 'non small cell lung cancer' #9. 'lung tumor' #10. 'lung cancer' #11. hispanic OR 'south and central america' #12. 'hispanic' #13. 'latin american' #14. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 #15. #11 OR #12 OR #13 #16. 'pd-l1 test kit' #17. 'pdl1 gene' #18. 'programmed death 1 ligand 1' #19. ligand AND programmed AND 'death ligand 1' #20. 'programmed death 1 receptor' #21. 'programmed cell death protein 1 antibody' #22. 'programmed cell death protein 1 inhibitor' #23. #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 #24. #14 AND #15 AND #23 #25. #14 AND #15 AND #23 AND ([embase]/lim OR [medline]/lim OR [preprint]/lim OR [pubmed-not-medline]/lim)

Figure S1 Meta-analysis of PD-L1 expression excluded squamous cell carcinoma. (A) TPS expression ≥1%. (B) TPS expression 1–49%. (C) TPS expression ≥50%. CI, confidence interval; PD-L1, programmed cell death ligand 1; TPS, tumoral proportion score.

Table S2 Assessment of the quality of evidence and risk of bias for each study using the recommendations of the JBI

Author (ref)	Year	Country	Quality assessment
Pilnik et al. (13)	2019	Argentina	Abstract. Quality wasn't assessed
Ruiz et al. (26)§	2024	Argentina	Meets JBI criteria
Andreis et al. (14)§	2019	Brazil	Meets JBI criteria
Cabral (29)§	2021	Brazil	Outcome measurement concerns
Alves Da Silva et al. (25)§	2019	Brazil	Meets JBI criteria
Gelatti et al. (28)	2020	Brazil	Meets JBI criteria
Oliveira et al. (27)§	2019	Brazil	Meets JBI criteria
Alves Pinto et al. (30)‡	2022	Brazil	Meets JBI criteria
Alarcón et al. (33)§	2021	Colombia	Lack of description in measurement of outcomes and lack of explanation in statistical analysis
Fernández-Trujillo et al. (32)‡	2020	Colombia	Meets JBI criteria
Cardona et al. (31)‡	2020	Colombia	Meets JBI criteria
Sua et al. (15)	2019	Colombia	Abstract. Quality wasn't assessed
Fernández Freire et al. (16)‡	2023	Ecuador	Meets JBI criteria
Avilés-Salas et al. (17)§	2022	Mexico	Meets JBI criteria
Sosa et al. (18)	2022	Mexico	Abstract. Quality wasn't assessed
Cordeiro de Lima et al. (22)‡	2022	Multicentic*	Meets JBI criteria
Raez et al. (23)‡	2022	Multicentic**	Meets JBI criteria
Werutsky et al. (24)	2022	Multicentric***	Abstract. Quality wasn't assessed
Paytan et al. (19)	2021	Peru	Abstract. Quality wasn't assessed
Shum et al. (21)	2017	USA	Abstract. Quality wasn't assessed
Saravia et al. (20)	2019	USA	Abstract. Quality wasn't assessed

§, cross sectional studies; ‡, longitudinal studies; *, multicentric: Mexico, Colombia, Costa Rica, Argentina, Chile, Peru, Brazil , H/L in US; **, multicentric: H/L in US, Mexico, Colombia; ***, multicentric: Argentina, Brazil, Colombia , Mexico. JBI, Joanna Briggs Institute; H/L, Hispanic/Latino.